Nuvalent (NUVL) Change in Acquisitions & Divestments (2022 - 2026)
Nuvalent's (NUVL) quarterly Change in Acquisitions & Divestments came in at $181.5 million in Q1 2026, down 40.0% YoY from $302.6 million in Q1 2025, and up 11.31% on a QoQ basis from $163.1 million in Q4 2025.
Analysis
Nuvalent (NUVL) Change in Acquisitions & Divestments (2022 - 2026) Analysis & Trends
Nuvalent (NUVL) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $181.5 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments fell 40.0% year-over-year to $181.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $812.6 million (up 19.9% YoY) and the FY2025 annual result came in at $933.7 million, up 106.82% from the prior year.
- Change in Acquisitions & Divestments grew to $181.5 million in Q1 2026, from $163.1 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $302.6 million in Q1 2025 to a low of $27.0 million in Q1 2022.
- A 5-year average of $122.6 million and a median of $105.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
- Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments soared 296.85% — and 2026, when it slumped 40.0%.
- Tracing NUVL's Change in Acquisitions & Divestments over 5 years: stood at $97.2 million in 2022, then climbed by 13.62% to $110.5 million in 2023, then increased by 28.96% to $142.4 million in 2024, then increased by 14.5% to $163.1 million in 2025, then rose by 11.31% to $181.5 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $181.5 million (Q1 2026), $163.1 million (Q4 2025), and $232.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 181.55 Mn |
| Dec 31, 2025 | 163.10 Mn |
| Sep 30, 2025 | 232.44 Mn |
| Jun 30, 2025 | 235.55 Mn |
| Mar 31, 2025 | 302.59 Mn |
| Dec 31, 2024 | 142.45 Mn |
| Sep 30, 2024 | 127.71 Mn |
| Jun 30, 2024 | 105.04 Mn |
| Mar 31, 2024 | 76.25 Mn |
| Dec 31, 2023 | 110.46 Mn |
| Sep 30, 2023 | 61.61 Mn |
| Jun 30, 2023 | 83.21 Mn |
| Mar 31, 2023 | 60.69 Mn |
| Dec 31, 2022 | 97.22 Mn |
| Sep 30, 2022 | 37.13 Mn |
| Jun 30, 2022 | 40.90 Mn |
| Mar 31, 2022 | 27.00 Mn |